I simply would add that I ask my colleagues to oppose this amendment. As far as the jobs increase, or lack thereof, that my colleague speaks of, we have had the slowest growth rate in jobs in the history of this country. There are millions…
Tom Marino
The Public Record
Tom Marino is a Republican politician from Pennsylvania who served as a member of the U.S. House of Representatives from 2011 to 2019. During his time in Congress, he represented Pennsylvania's 10th congressional district. Marino focused on issues such as healthcare, veterans' affairs, and drug policy, advocating for measures to combat the opioid crisis. He was also involved in efforts to reduce government spending and promote economic growth in his district. After leaving Congress, Marino has remained active in various capacities but has not held a public office since his departure.
This amendment would strike from the bill the Separation of Powers Restoration Act and the essential judicial review provisions of the Regulatory Accountability Act. It, too, should be rejected for those reasons. In addition, the bill…
I demand a recorded vote. The Acting CHAIR. Pursuant to clause 6 of rule XVIII, further proceedings on the amendment offered by the gentleman from Rhode Island will be postponed. Amendment No. 10 Offered by Mr. Johnson of Georgia The…
I claim the time in opposition to the amendment. The Acting CHAIR (Mr. Fortenberry). The gentleman from Pennsylvania is recognized for 5 minutes.
I believe in the Constitution just like everyone else does, and primarily we, as congressmen and congresswomen, have a responsibility to make the laws, not unelected bureaucrats who have no experience in a lot of the areas where they are…
I claim the time in opposition to the amendment. The Acting CHAIR (Mr. Young of Iowa). The gentleman from Pennsylvania is recognized for 5 minutes.
The REINS Act doesn't prevent the bureaucracy, the agencies, from making recommendations and suggestions to Congress. It simply says Congress will have the last word and not a handful of bureaucrats, and many of them don't even have…
Just to reiterate what our position is, it is about time that we in D.C.--in Congress--take our responsibility back from unelected bureaucrats and make these decisions. We have seen, over the past 8 years, what overburdensome regulation…
This amendment exempts from the bill any rule pertaining to health or public safety. Health and public safety regulations done properly serve important goals, and the bill does nothing to frustrate the effective achievement of those goals…
I demand a recorded vote. The Acting CHAIR. Pursuant to clause 6 of rule XVIII, further proceedings on the amendment offered by the gentlewoman from Florida will be postponed. Amendment No. 5 Offered by Mr. Cicilline The Acting CHAIR. It…
I claim the time in opposition to this amendment. The Acting CHAIR (Mr. Byrne). The gentleman from Pennsylvania is recognized for 5 minutes.
I fully expect that President-elect Trump and President Tsai will have a productive relationship that benefits both of our economies.
I am hopeful that this pivotal alliance will be rekindled from the top down and remain the force for good that it can be.
Congress has been vigilant about applying pressure on the DPRK, and I anticipate that it will continue to look forward to new levers to stop North Korea's belligerent and dangerous behavior.
Action on the REVIEW Act is a reasonable step on our part to continue proper and responsible regulatory reform. In the end, this is a bill that encourages smaller, sensible rulemaking. When the costs are borne on the back of our…
Then in 35 seconds, Dr. Ketcham, your testimony lays out that there are many barriers experienced by first responders and medical professionals in an effort to respond to these overdoses.
No one wishes for a friend, family member, or a loved one to succumb to addiction.
Clearly, this is anti-competitive conduct that should be swiftly and harshly punished.
If Congress wants to help increase access to these drugs, then something must be done to curtail the cost of these lifesaving medications.
It is critical that our polices continue to place a high value on innovation.
Unfortunately, for many, these concerns extend to the markets for other lifesaving treatments as well.
I am personally concerned about the high cost of the new treatment for Hepatitis C, a virus that affects more than 4 million Americans and which costs nearly $75,000.





